Breakthrough Device Designation Granted for Roche’s VENTANA TROP2 RxDx Device
Roche’s VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Read MorePosted by Chris Wolski | May 5, 2025 | Lung Cancer |
Roche’s VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Read MorePosted by Chris Wolski | Apr 22, 2025 | Cancer |
Liquid biopsy is a groundbreaking, non-invasive method for early cancer detection and monitoring, offering significant clinical potential.
Read MorePosted by Chris Wolski | Apr 9, 2025 | Molecular Diagnostics |
A breakthrough discovery that water vapor causes bubble formation in PDMS-based PCR chips has led to a high-pressure liquid seal technique.
Read MorePosted by Chris Wolski | Mar 20, 2025 | Lung Cancer |
Lung cancer screening has increased overall, but significant disparities remain, particularly among rural and underserved populations.
Read MorePosted by Chris Wolski | Mar 11, 2025 | Unknown Origin & Other Cancer Types |
A study on neuroblastoma with bone or bone marrow metastasis (NB-BBM) used deep learning to uncover biomarkers.
Read More